Delta Phase Matrix

DSIP + GABA + Melatonin + Pinealon

Delta Phase Matrix (DSIP + GABA + Melatonin + Pinealon) is a cognitive & mood research compound. Sleep-architecture blend — DSIP modulates deep-sleep signaling, GABA calms neural excitability, melatonin sets the circadian timing, and Pinealon supports pineal/neuronal function.

How Delta Phase Matrix works

Sleep-architecture blend — DSIP modulates deep-sleep signaling, GABA calms neural excitability, melatonin sets the circadian timing, and Pinealon supports pineal/neuronal function.

Proposed benefits

Researched for focus, memory, neuroprotection, mood and stress resilience.

Where to get Delta Phase Matrix

The evidence for Delta Phase Matrix

Graded by what exists behind each claim.

✅ Clinically validated

• No trial of the blend. It combines DSIP with other sleep-directed ingredients — read each component's clinical tier, and note that DSIP's own human evidence is small, old and unreplicated.

📊 Correlative data

• Used as a sleep protocol rather than an acute sedative. Reported experience is variable in the same way DSIP's is, which is unsurprising given it is the active anchor.

🧪 Theoretical / extrapolated

• Combines a sleep-architecture peptide with supporting ingredients, on the logic that sleep depth and sleep onset are different problems.
• A blend cannot be more evidenced than its weakest anchor. The mechanistic case is coherent; the evidence underneath it is DSIP's, with all the caveats that carries.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Delta Phase Matrix actually does

Four ingredients, four completely different levels of evidence, and they are not in the order the product name implies. Taken one at a time.

Melatonin is the only component with a mechanism that is both established and dose-relevant. It is not a sedative. It is a chronobiotic: it binds MT1 and MT2 receptors in the suprachiasmatic nucleus and shifts the phase of the circadian clock, with the direction of the shift determined by the time of administration relative to a person's own melatonin onset. That is why the human phase-response curve work compared 0.5 mg against 3.0 mg across three days of daily dosing Burgess 2010 — the field's real question about melatonin has always been when, not how much.

DSIP is the ingredient the product is named after and it is the weakest link in the chain. The peptide was isolated from rabbit cerebral venous blood in 1977 and its amino-acid analysis, sequence and synthesis were published the following year Schoenenberger 1978. Since then: the DSIP gene has never been isolated, nor the protein, nor any receptor for it, and a review by researchers who worked on it concludes that the hypothesis of DSIP as a sleep factor is extremely poorly documented and still weak Kovalzon 2006. The same review notes something sharper: certain artificial DSIP structural analogs showed significant slow-wave-sleep-promoting activity in rabbits and rats — but not DSIP itself.

GABA in an oral or nasal spray runs into the barrier that defines this whole area. Gamma-aminobutyric acid is small, zwitterionic and hydrophilic, and the blood-brain barrier is built to exclude exactly that profile. This is not a controversial claim; it is the reason an entire class of GABA derivatives with added lipophilic groups exists. Whatever GABA in a spray does, a direct central GABAergic effect is the least likely explanation.

Pinealon is a synthetic tripeptide from the ultrashort-peptide program, and its proposed mechanism is transcriptional rather than receptor-mediated. The Glu-Asp-Arg tripeptide has been proposed to act on gene expression and protein synthesis Khavinson 2021, and the transport question — how a charged tripeptide reaches a cell interior — is answered in that literature by the di- and tripeptide carriers of the POT family and the L-type amino acid transporters Khavinson 2022. Note what that implies: the proposed route is a transporter, which saturates, rather than diffusion, which does not.

Cell, rodent, human — and where it stops

Melatonin, in humans, at scale. A meta-analysis of 19 studies in 1,683 subjects with primary sleep disorders examined sleep latency, total sleep time and sleep quality against placebo Ferracioli-Oda 2013. This is the one component of the blend with a proper evidence pyramid underneath it, and its effects are consistent and modest rather than dramatic.

DSIP, in humans — and the details of these two studies decide what the product can claim. The first was six normal volunteers, double-blind cross-over, DSIP given as slow intravenous infusion at 25 nmol/kg in the morning. Subjects reported immediate sleep pressure and total sleep time rose 59% within a 130-minute window against placebo, with delayed effects on the following night; EEG analysis showed no sedation in the classic pharmacologic way Schneider-Helmert 1981. The second was six middle-aged chronic insomniacs, again 25 nmol/kg intravenously: longer sleep duration, fewer interruptions, slightly more REM, effects visible for up to six hours — and a slight arousing effect in the first hour, with sleep promotion only from the second Schneider-Helmert 1981.

Now state the obstacle in the terms that matter for a spray. Twelve people, in 1981, dosed by slow intravenous infusion. 25 nmol/kg in a 70 kg adult is about 1.75 micromoles delivered directly into the circulation. A nasal or oral spray states a volume, not a molar dose, and no bioavailability figure exists for this peptide by either route. The human DSIP evidence cannot be transferred to this product without an absorption number that nobody has measured. And the first-hour arousing effect Schneider-Helmert 1981 is the opposite of what a bedtime spray is sold to do.

GABA, in rodents. The GABA and L-theanine mixture study that is usually cited for this ingredient used pentobarbital-induced sleep testing and EEG in rodents, with gene-expression work alongside Kim 2019. Two things follow: the species is not human, and the intervention was a mixture, so nothing in it isolates what GABA alone did.

Pinealon, in the ultrashort-peptide literature. The proposed mechanism is gene-expression regulation Khavinson 2021 with carrier-mediated cellular entry Khavinson 2022. There is no randomized human sleep trial of this tripeptide.

And the obstacle that applies to the product rather than to any ingredient: nothing has ever been tested as this combination. Four components, one spray, no trial of the mixture, and one of the four — melatonin — carries almost all the evidence in the vial.

Delta Phase Matrix pharmacokinetics — how much of it actually gets in

The card says varies by component, which is true and is also the reason a single spray cannot be dosed correctly for all four. Here is each clock.

Melatonin. Oral melatonin is absorbed quickly and subject to extensive first-pass hepatic metabolism by CYP1A2, with wide between-person variation in the fraction surviving it — which is why the same milligram dose produces very different blood concentrations in different people. Its elimination half-life is short, on the order of 30 to 60 minutes, and that is precisely why the phase-response work dosed it repeatedly across three days and compared timing rather than escalating the dose Burgess 2010. A sublingual or nasal route bypasses first-pass metabolism and therefore raises exposure from the same nominal milligram, which makes the quantity in a spray harder to reason about, not easier.

DSIP. A linear peptide with free termini and no protective modification, cleared by plasma and tissue peptidases. The human studies gave it by slow intravenous infusion Schneider-Helmert 1981Schneider-Helmert 1981 — the choice of a slow infusion rather than a bolus is itself evidence that the investigators were compensating for rapid clearance. Across the gut it faces pepsin, pancreatic proteases and brush-border aminopeptidases, so oral bioavailability is effectively nil; across nasal mucosa, absorption of a peptide of this size is low and highly variable.

GABA. The relevant number is not a half-life but a permeability. Its charge and hydrophilicity keep it out of the brain at the barrier, and any systemic GABA is also acting on peripheral GABA receptors in the enteric nervous system — which is a plausible route to a subjective calming effect that does not require central penetration at all, and is the honest version of the claim.

Pinealon. A charged tripeptide, so passive diffusion is not the route; the proposed mechanism is carrier-mediated uptake by PepT-family and LAT-family transporters Khavinson 2022. Carrier-mediated uptake saturates, which predicts a ceiling: above the transporter's capacity, more peptide in the spray produces no more peptide in the cell. Nobody has measured where that ceiling is.

The combined consequence. One actuation delivers a 30-minute molecule, a peptidase-limited molecule, a molecule that may not cross the barrier, and a transporter-limited molecule. There is no single dosing time that is correct for all four, and the component whose timing matters most — melatonin — is the one whose effect depends on the clock rather than on the dose Burgess 2010.

What would have to be true, and how you would know it was not

Three predictions with instruments and windows. The third argues that most of this product is doing nothing.

1. Sleep onset latency should shorten and it should be attributable to timing, not to the spray. Melatonin's own meta-analytic evidence covers latency, total sleep time and quality Ferracioli-Oda 2013, and its phase-shifting action depends on when it is taken relative to endogenous onset Burgess 2010. Prediction: two weeks of actigraphy with a fixed dosing time produces a measurable reduction in sleep onset latency; moving the same dose two hours later changes the effect. If timing does not matter, the component doing the work is not the melatonin.

2. Morning cortisol and evening cortisol should be measured before blaming the product for not working. A flattened or inverted cortisol rhythm is a common cause of both delayed onset and early waking, and it is the confounder that makes any sleep product look inconsistent. Prediction: in a person whose cortisol rhythm is disordered, a chronobiotic will underperform because it is acting on one arm of a two-arm system. That is falsifiable in either direction with a four-point salivary curve.

3. Against the product: three of the four ingredients should be removable without changing the outcome. The DSIP human evidence is twelve people given intravenous peptide in 1981 Schneider-Helmert 1981Schneider-Helmert 1981, its status as a sleep factor is described in the literature as poorly documented and weak Kovalzon 2006, the GABA evidence for this use is a rodent mixture study Kim 2019, and Pinealon has no human sleep trial. Prediction: an equivalent dose of plain melatonin at the same time of night produces the same actigraphy result as the four-component spray. This is a within-person crossover anyone can run in four weeks, it is the single most useful experiment available for this product, and if it comes out the other way — the blend beating melatonin alone — that would be genuinely new information about DSIP.

What nobody has tested yet

Four things nobody has measured, and the first one is foundational.

Whether DSIP crosses a nasal or oral mucosa at all. Every human result for this peptide used intravenous infusion Schneider-Helmert 1981Schneider-Helmert 1981. No published study has measured plasma DSIP after intranasal or oral administration in a person. Until somebody does, a spray containing DSIP is an untested delivery of a poorly documented molecule, and that is not a criticism of the product so much as a description of the state of the evidence.

Whether a DSIP analog would work better than DSIP. The review's most concrete observation is that artificial structural analogs, and a naturally occurring dermorphin-related decapeptide structurally similar to DSIP in five of nine positions, promoted slow-wave sleep where DSIP itself did not Kovalzon 2006. That is a specific, actionable lead that has been sitting unexplored for two decades.

What the first-hour arousing effect is. One of the two human studies reported a slight arousing effect in the first hour with sleep promotion only from the second Schneider-Helmert 1981. Nobody has reproduced or explained it. If it is real it has an obvious practical consequence for when a bedtime product should be taken, and no product built on this peptide accounts for it.

Whether the tripeptide reaches anything. The transport hypothesis is carrier-mediated Khavinson 2022; whether an intranasally delivered Glu-Asp-Arg tripeptide reaches central tissue in a measurable concentration has not been shown in a person. A labeled-peptide distribution study would answer it and would apply to the whole ultrashort-peptide category, not just this one.

Delta Phase Matrix — its own safety story, not its class's

The safety story here is unusually mild and unusually uninformative, and both halves of that deserve saying.

What was actually observed with DSIP in people. In the first human study the compound was well tolerated with no psychologic, physiologic or biochemical side effects observed Schneider-Helmert 1981, and the second reported no day-time sedation or other side effects Schneider-Helmert 1981. That is reassuring for a single intravenous dose in six people and it is not a safety dataset for repeated nightly use over months.

Melatonin is the component most likely to produce an actual effect and therefore an actual problem. Its risk is not toxicity, it is phase: taken at the wrong point relative to a person's own rhythm it shifts the clock the wrong way, and the result is someone taking more of a product that is causing the problem it is being taken for Burgess 2010. It also interacts with the medications people take for sleep and with anything metabolized through the same hepatic route.

The blend format hides the dose. A 15 mL spray dosed ‘as directed’ does not state how much melatonin an actuation delivers. Since the melatonin literature's central question is dose and timing Ferracioli-Oda 2013Burgess 2010, a product that obscures the milligram figure removes the one variable the evidence says to control.

And the honest limit of what this page can say. Persistent insomnia is frequently a symptom of something else — sleep apnea, a mood disorder, a thyroid problem, a medication. None of those is addressed by a chronobiotic, and a product that makes the nights tolerable without changing the cause is a way of not finding out. That is not a safety warning about the ingredients; it is the more important risk of the category.

Sources read for this page

• Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle.. J Neurochem 2006 · PMID 16539679
• Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.. Int J Clin Pharmacol Ther Toxicol 1981 · PMID 6895513
• Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.. Experientia 1981 · PMID 7028502
• Schoenenberger GA, Maier PF, Tobler HJ, Wilson K, Monnier M. The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide.. Pflugers Arch 1978 · PMID 568769
• Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One 2013 · PMID 23691095
• Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. Journal of Clinical Endocrinology and Metabolism 2010 · PMID 20410229
• Kim S, et al. GABA and l-theanine mixture decreases sleep latency and improves NREM sleep. Pharmaceutical Biology 2019 · PMID 30707852
• Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules 2021;26(1):159 · PMID 33396470
• Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081

Delta Phase Matrix — safety, predicted from mechanism

Delta Phase Matrix — interference & stacking

Bloodwork to run alongside Delta Phase Matrix

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

Delta Phase Matrix — frequently asked questions

Delta Phase Matrix inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Delta Phase Matrix is used for

Delta Phase Matrix appears under 1 goal in the goal router.

Related Cognitive & Mood compounds

← Explore the full Protocol Vault

↑ Back to on this page